510(k) device
Eversense 365 Continuous Glucose Monitoring (CGM) System
Senseonics, Incorporated · Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA, Class II) · First FDA decision Sep 16, 2024, newest Sep 16, 2024Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Eversense 365"
MAUDE reports
5
Brand "Eversense 365", since 2015
PubMed studies
3
Mentioning "Eversense 365"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eversense 365 Continuous Glucose Monitoring (CGM) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38662CGS Administrators, LLCUpdated Sep 29, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38623Wellpoint FederalUpdated Jul 14, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38686WPS Insurance CorporationUpdated Jun 18, 2026
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38657Noridian Healthcare Solutions, LLCUpdated Oct 14, 2025
- Home Health Plans of Care: Monitoring Glucose Control in the Medicare Home Health Population with Type II Diabetes MellitusLocal determinationIn effectL35132Palmetto GBAUpdated Apr 9, 2025
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38743Palmetto GBAUpdated Jul 19, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38664First Coast Service Options, Inc.Updated Jun 21, 2024
- Implantable Continuous Glucose Monitors (I-CGM)Local determinationIn effectL38617Novitas Solutions, Inc.Updated Jun 21, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Eversense 365", any status and sponsor, newest update first.
Senseonics, Inc.Public (SENS)
NCT07386340 · 80 participants (planned) · Start Dec 29, 2025 · Primary completion Dec 2027
Device: Continuous Glucose Monitoring System · For: Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California
- ROME GS System StudyRecruiting
Senseonics, Inc.Public (SENS)
NCT07518004 · 60 participants (planned) · Start Feb 12, 2026 · Primary completion Aug 2028
Device: Continuous Glucose Monitoring System · For: Diabetes; Diabetes Melletus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California; Walnut Creek, California; San Antonio, Texas · 4 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eversense 365", and for the whole product code for context.
This brand
5 reports: 4 malfunction, 0 injury, 0 death
Whole product code SBA
4,136 reports: 3,215 malfunction, 903 injury, 1 death
Newest reports for this brand
MW6002861 · Received Sep 24, 2026
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Inadequate Instructions for Non-Healthcare Professional
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- Eversense 365 CGMOther
MW6001940 · Received Sep 8, 2026 · Event dated Aug 10, 2026
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings; Calibration Problem
Patient problem as coded: Unspecified Infection; Pain; Fluid Discharge
- EVERSENSE 365 SENSORMalfunction
3009862700-2025-01565 · Received Oct 8, 2025 · Event dated Sep 8, 2025
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
Device problem as coded: Imprecision
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Eversense 365"[tiab]. The summary above synthesizes these.
- Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.
Bailey TS, Liljenquist DR, Denham DS, et al. · Diabetes Technol Ther · 2025Multicenter Study
- Real-World Data from U.S. Commercial Users of the 365-Day Implantable Eversense Continuous Glucose Monitoring System, Including with the Twiist Automated Insulin Delivery System Integration.
Kaufman F, Jain I, Han S, et al. · Diabetes Technol Ther · 2026
- Severe Hyperglycemia due to Calibration Misuse in an Eversense-365 Implantable Continuous Glucose Monitoring System.
Moeller J · AACE Endocrinol Diabetes · 2026Case Reports
Other devices of this type
Also filed under product code SBA.
- Eversense AP CGM SystemSenseonics, Incorporated · De Novo 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.